"With minimal radiation exposure to healthy tissues and rapid dose fall-off, Electronic Brachytherapy delivers targeted treatment that is professionally validated and patient friendly," said Michael Klein, President and CEO of Xoft. "When eBx was first introduced as an X-ray-based, electronic treatment option for early stage breast cancer, it represented a paradigm shifting technology, supporting the development of a suite of interventional radiation oncology tools. As we have launched additional applications and indications, we are pleased with the strong support and rapid adoption of these multi-disciplinary approaches for use of Electronic Brachytherapy to deliver safe, targeted treatment."
About Xoft, Inc.
Xoft develops Electronic Brachytherapy (eBx) systems based upon miniaturized X-ray tube technology for the practice of radiation oncology in virtually any clinical setting, eliminating the need for heavily shielded environments. The Axxent® treatment platform provides a therapeutic dose of radiation directly to the region at risk with minimal radiation exposure to surrounding healthy tissue and without the complex handling, resource logistics and costs associated with using radioactive isotopes. Xoft aligns with the Nuclear Regulatory Commission's (NRC) directive to seek alternatives for radioactive medical isotopes. Commercially available for treatment of early stage breast cancer, skin cancer and endometrial cancer indications, the Axxent Electronic Brachytherapy System is also cleared for use in the treatment of other cancers or conditions where radiation therapy is indicated. For information, visit '/>"/>
|SOURCE Xoft, Inc.|
Copyright©2010 PR Newswire.
All rights reserved